Image Source: AsiaOne
Athenex Provides Second Quarter 2021 Corporate and Financial UpdateGlobeNewswireAugust 05, 2021Updated investors on FDA Type A Meeting for oral paclitaxel Klisyri® approved by the European Commission in July 2021 KUR-501 GD2 CAR-NKT Phase 1 data in neuroblastoma presented at ASGCT 2021 Abstract for oral paclitaxel + pembrolizumab Phase 1 combination study accepted for ESMO Congress 2021 Management to host conference call and webcast today at 8:00 a.m. ET BUFFALO, N.Y., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the second quarter ended June 30, 2021.
Source: AsiaOne